With a nod from the FDA, Teva enters white-hot migraine market
Teva’s Ajovy becomes the second approved CGRP migraine therapy, following Amgen’s Aimovig.
Commercial
7 must-haves for effective market access programs
How does one create an effective market access program in the current healthcare environment? Experts share seven tips for success.
After failure of generic fish oil trial, some caution against read-across to Vascepa study
Amarin’s Vascepa trial is set to read out results by the end of September.
Got name? A peek into the sometimes bizarre land of pharma brand-naming
As more medications are approved, pharma companies are being pushed farther afield into a land of bizarre — but hopefully still memorable and vaguely meaningful — drug names.
Behind the Exact Sciences/Pfizer Cologuard co-promotion deal
The companies plan to make the most of favorable market access conditions for the at-home colon cancer screening test.
Pfizer lawsuit could clear path for biosimilars
Biosimilars have only been in the market for three years, but they have struggled to compete with their branded equivalents.
Novo Nordisk’s Ozempic takes on Lilly’s Trulicity in DTC showdown
The two diabetes rivals air competing TV spots as they compete for GLP-1 supremacy.
Q&A: Matt McNally on the road ahead for Outcome Health and the state of the POC union
Matt McNally, CEO of Outcome Health, shares his thoughts on post-controversy Outcome Health and the overall state of the point-of-care union.
Media buyers form group to advance standards in POC
Among the group’s members are media agencies that had pulled healthcare ad spend from the POC channel in the wake of a scandal 10 months ago.
POC community makes good on promises of transparency and accountability
After a scandal with one of point of care’s biggest players, we examine how the community is living up to its promise of greater transparency.
Want to read more?
Please login or register first to view this content.
